Study S002048

Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - a Pilot Study

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT05897372
Acronym: WP3
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: NONE
Status: TERMINATED
Enrollment: 1
Start: 2023-08-01
Primary completion: 2024-09-23
Lead sponsor: Iain Bressendorff
Conditions: Diabetic Kidney Disease
Interventions: DRUG:ACEi / ARB, SGLT2i, finerenone, semaglutide, pentoxifylline, hydrochlorthiazide, baricitinib
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

urine albumin/creatinin-ratio (UACR) reduction to less than 50% of baseline [after 9 months of treatment]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.